Hexamethylamine and VP-16 an Oral Regimin for HIV Malignancies: A Phase I/II Trial

Inclusion Criteria

DISEASE CHARACTERISTICS: Documented HIV antibody positive Histologically confirmed, by
biopsy, non-Hodgkin's lymphoma that is in complete remission or stable/partial remission
for a minimal period of one month And/or Histologically confirmed, by biopsy, Kaposi's
sarcoma without stable disease

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100%
Hematopoietic: Absolute neutrophil count at least 500/mm3 Platelet count greater than
25,000/mm3 (unless secondary to lymphoma) Hepatic: Transaminases less than 5 times upper
limit of normal AND Bilirubin less than 2.0, unless secondary to lymphoma Renal:
Creatinine less than 2.0 mg/dL OR Creatinine clearance at least 60 mL/min Dose reduction
of 21% if creatinine clearance 10-50 mL/min Dose reduction of 50% if creatinine clearance
less than 10 mL/min Cardiovascular: No active cardiac arrhythmia or angina Pulmonary: Must
exclude Pneumocystis carinii pneumonia if there is any suspicion of infection Other: No
uncontrolled infections Not pregnant or nursing Adequate contraception for fertile
patients

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Patients with
concurrent antiretroviral therapy should be on a stable dose of that therapy for at least
one month prior to entry No concurrent cytotoxic chemotherapy Endocrine therapy: No
concurrent hormone therapy Radiotherapy: No concurrent radiotherapy Surgery: Not specified